Molecular mode of action of NKP-1339 – a clinically investigated ruthenium-based drug – involves ER- and ROS-related effects in colon carcinoma cell lines

Sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) is a clinically investigated ruthenium-based metal complex, which shows promising results in solid tumors, such as non-small cell lung cancer, colorectal carcinoma, and most distinctively in gastrointestinal neuroendocrine tumors....

Descripción completa

Detalles Bibliográficos
Autores principales: Flocke, Lea S., Trondl, Robert, Jakupec, Michael A., Keppler, Bernhard K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Preclinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859864/
https://www.ncbi.nlm.nih.gov/pubmed/26988975
http://dx.doi.org/10.1007/s10637-016-0337-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859864/
https://www.ncbi.nlm.nih.gov/pubmed/26988975
http://dx.doi.org/10.1007/s10637-016-0337-8

Ejemplares similares